Effects of ranibizumab (Lucentis ®) and bevacizumab (Avastin®) on human corneal endothelial cells
Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are ...
Source: BMC Ophthalmology - Category: Opthalmology Authors: Patrick R. Merz, Nina R öckel, Seda Ballikaya, Gerd U. Auffarth and Ingo Schmack Tags: Research article Source Type: research